Cargando…
Preferred antiretroviral drugs for the next decade of scale up
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for bot...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International AIDS Society
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494169/ https://www.ncbi.nlm.nih.gov/pubmed/23010379 http://dx.doi.org/10.7448/IAS.15.2.17986 |
_version_ | 1782249371503427584 |
---|---|
author | Andrieux-Meyer, Isabelle Calmy, Alexandra Cahn, Pedro Clayden, Polly Raguin, Gilles Katlama, Christine Vitoria, Marco Levin, Andrew Lynch, Sharonann Goemaere, Eric Ford, Nathan |
author_facet | Andrieux-Meyer, Isabelle Calmy, Alexandra Cahn, Pedro Clayden, Polly Raguin, Gilles Katlama, Christine Vitoria, Marco Levin, Andrew Lynch, Sharonann Goemaere, Eric Ford, Nathan |
author_sort | Andrieux-Meyer, Isabelle |
collection | PubMed |
description | Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings. |
format | Online Article Text |
id | pubmed-3494169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-34941692012-11-26 Preferred antiretroviral drugs for the next decade of scale up Andrieux-Meyer, Isabelle Calmy, Alexandra Cahn, Pedro Clayden, Polly Raguin, Gilles Katlama, Christine Vitoria, Marco Levin, Andrew Lynch, Sharonann Goemaere, Eric Ford, Nathan J Int AIDS Soc Commentary Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings. International AIDS Society 2012-09-18 /pmc/articles/PMC3494169/ /pubmed/23010379 http://dx.doi.org/10.7448/IAS.15.2.17986 Text en © 2012 Andrieux-Meyer I et al; licensee International AIDS Society http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Andrieux-Meyer, Isabelle Calmy, Alexandra Cahn, Pedro Clayden, Polly Raguin, Gilles Katlama, Christine Vitoria, Marco Levin, Andrew Lynch, Sharonann Goemaere, Eric Ford, Nathan Preferred antiretroviral drugs for the next decade of scale up |
title | Preferred antiretroviral drugs for the next decade of scale up |
title_full | Preferred antiretroviral drugs for the next decade of scale up |
title_fullStr | Preferred antiretroviral drugs for the next decade of scale up |
title_full_unstemmed | Preferred antiretroviral drugs for the next decade of scale up |
title_short | Preferred antiretroviral drugs for the next decade of scale up |
title_sort | preferred antiretroviral drugs for the next decade of scale up |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494169/ https://www.ncbi.nlm.nih.gov/pubmed/23010379 http://dx.doi.org/10.7448/IAS.15.2.17986 |
work_keys_str_mv | AT andrieuxmeyerisabelle preferredantiretroviraldrugsforthenextdecadeofscaleup AT calmyalexandra preferredantiretroviraldrugsforthenextdecadeofscaleup AT cahnpedro preferredantiretroviraldrugsforthenextdecadeofscaleup AT claydenpolly preferredantiretroviraldrugsforthenextdecadeofscaleup AT raguingilles preferredantiretroviraldrugsforthenextdecadeofscaleup AT katlamachristine preferredantiretroviraldrugsforthenextdecadeofscaleup AT vitoriamarco preferredantiretroviraldrugsforthenextdecadeofscaleup AT levinandrew preferredantiretroviraldrugsforthenextdecadeofscaleup AT lynchsharonann preferredantiretroviraldrugsforthenextdecadeofscaleup AT goemaereeric preferredantiretroviraldrugsforthenextdecadeofscaleup AT fordnathan preferredantiretroviraldrugsforthenextdecadeofscaleup |